Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

422 results about "AIDS diagnosis" patented technology

Epilepsy prediction system based on synchronously acquired electroencephalogram-electrogastrogram signals

The invention relates to the field of disease prediction, in particular to an epilepsy prediction system based on synchronously acquired electroencephalogram-gastric electrical signals, comprising: a data acquisition module for acquiring data including electroencephalogram data and gastrointestinal electrical data; the first analysis module is used for obtaining an average electrode inconsistency index of the first channel and the second channel based on a first model according to the time sequence data; and the prediction module is used for comparing the average electrode inconsistency index of the subject with a preset evaluation threshold value so as to predict an epileptic. The system provided by the invention can more accurately and efficiently distinguish epilepsy patients from healthy people, and can be used as an auxiliary diagnosis tool to be applied to primary screening of epilepsy of relatively large people (such as communities and physical examination centers).
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Epilepsy prediction system based on synchronously acquired electroencephalogram-electrogastrogram signals

ActiveCN120419912ASensorsDiagnostic recording/measuringElectrogastrogramAIDS diagnosis
The invention relates to the field of disease prediction, in particular to an epilepsy prediction system based on synchronously acquired electroencephalogram-gastric electrical signals, comprising: a data acquisition module for acquiring data including electroencephalogram data and gastrointestinal electrical data; the first analysis module is used for obtaining an average electrode inconsistency index of the first channel and the second channel based on a first model according to the time sequence data; and the prediction module is used for comparing the average electrode inconsistency index of the subject with a preset evaluation threshold value so as to predict an epileptic. The system provided by the invention can more accurately and efficiently distinguish epilepsy patients from healthy people, and can be used as an auxiliary diagnosis tool to be applied to primary screening of epilepsy of relatively large people (such as communities and physical examination centers).
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Development, preparation and application of carbapenemase immunochromatography kit

The invention discloses development, preparation and application of a carbapenemase immunochromatography kit, and belongs to the technical field of biological medicines. According to comparison of amino acid sequences of five common carbapenemase variants of KPC, IMP, NDM, VIM and OXA48 types, the immunogen is prepared from conserved epitope sequences obtained respectively. A mouse is immunized, and a specific antibody pair which is strong in affinity and can be combined with multiple variants is obtained through multi-platform screening. On the basis, the carbapenemase quintuplet detection kit is developed by utilizing an immunochromatography method, has the advantages of high sensitivity, good specificity, capability of covering various drug-resistant variants, capability of detecting multiple targets at one time and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

Primer probe combination and kit for HIV-1 (human immunodeficiency virus-1) nucleic acid detection

The invention relates to the field of biological detection, in particular to a primer probe combination and a kit for HIV-1 (human immunodeficiency virus-1) nucleic acid detection. The primer combination provided by the invention comprises a primer group I and / or a primer group II, the primer group I has a nucleotide sequence as shown in any of SEQ ID NO: 1 to SEQ ID NO: 4; the primer group II has a nucleotide sequence as shown in any of SEQ ID NO: 5 to SEQ ID NO: 8. The kit provided by the invention can be stored for 1 year at 2-8 DEG C, and has good stability. Meanwhile, the detection method and the kit provided by the invention have the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, clear result, high reliability and wide coverage. The invention has potential application prospects in detection and identification of HIV-1 and auxiliary diagnosis of HIV infected persons, and has great influence on prevention and treatment of AIDS and public health.
Owner:AUTOBIO DIAGNOSTICS CO LTD

Preparation of antibody capable of detecting multi-subtype KPC and application of kit of antibody

The invention discloses preparation of an antibody capable of detecting multi-subtype KPC and application of a kit of the antibody, and belongs to the field of biological medicine. According to the kit for detecting the common subtypes of KPC and the application of the kit, the mouse antibodies are prepared through immunization of conserved antigen epitopes of all the subtypes of KPC, in-vitro screening and pairing are carried out in multiple modes, then an antibody pair which is good in specificity and high in affinity and can be combined with multiple subtypes is obtained, the titer of the two antibodies can reach one million or above, and the kit is high in specificity, good in affinity and capable of being used for detecting the common subtypes of KPC. Amino acid sequences of a heavy chain variable region and a light chain variable region are obtained through sequencing, and rapid and stable expression can be realized after recombination. The product for detecting the carbapenem KPC is developed on the basis of an immunochromatography platform, and the kit has the advantages of high sensitivity, good specificity, good stability, capability of covering most epidemic KPC subtypes and rapidness and convenience in detection, and provides important help for clinical auxiliary diagnosis and medication guidance.
Owner:JIANGSU MEDOMICS MEDICAL TECHNOLOGY CO LTD

Autophagy biomarker related to depression, risk assessment model and application of autophagy biomarker

The invention discloses an autophagy biomarker related to depression, a risk assessment model and application of the autophagy biomarker. A group of autophagy related biomarkers for auxiliary diagnosis of depression are screened out through multi-dimensional screening of large sample data and a machine learning algorithm, the autophagy related biomarkers comprise the following genes: GABARAPL2, RB1CC1, FOS and ULK1, and differential expression of the autophagy related biomarkers is proved in chronic stress induced depression-like mouse cortical brain tissues. The invention also provides a risk assessment model for auxiliary diagnosis of depression, a logistic regression model is constructed by taking the biomarker as a feature, a score formula and a risk boundary value of depression risk assessment are determined, and multi-aspect assessment is carried out on the prediction performance of the model. The prediction model has good prediction accuracy and calibration degree, can efficiently and conveniently realize early diagnosis of depression, and improves the accuracy of depression treatment.
Owner:SOUTHEAST UNIV

Application of ABCG1 in diagnosis or auxiliary diagnosis of HIV (Human Immunodeficiency Virus) combined hyperlipidemia

The invention belongs to the field of biomedicine, and particularly relates to application of ABCG1 in diagnosis or auxiliary diagnosis of HIV (human immunodeficiency virus) combined hyperlipidemia. Through detection, the expression of the ABCG1 in the blood of a patient with HIV combined with hyperlipidemia is obviously reduced, the ABCG1 is verified to have the characteristics of high sensitivity and high specificity, whether hyperlipidemia exists in an HIV infected group or not can be diagnosed or diagnosed in an auxiliary manner by detecting the expression of the ABCG1, guidance is provided for early intervention of hyperlipidemia in the HIV infected group, and the method is suitable for clinical application. Wide clinical application prospects are realized.
Owner:核工业四一六医院

ERNA molecular marker for auxiliary diagnosis of intestinal cancer and application of eRNA molecular marker

The invention discloses an eRNA molecular marker for auxiliary diagnosis of intestinal cancer and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA58704, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention further provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of intestinal cancer. The kit comprises an eRNA58704 fluorescent quantitative PCR specific amplification primer, the nucleotide sequence of an upstream primer is 5 '-AAGTCAGGTTCATTCGTGC-3', and the nucleotide sequence of a downstream primer is 5 '-AAGTCAGGTTCATTCGTGC-3'. The nucleotide sequence of the downstream primer is 5 '-AGCAACCAACGCTCTTGTCA-3', and the kit further comprises a carbohydrate antigen CA19-9, and the kit has the advantages that early diagnosis of intestinal cancer patients on the molecular level can be conveniently, rapidly and efficiently achieved, pertinence, specificity and sensitivity are high, and early discovery and timely treatment of intestinal cancer are facilitated.
Owner:NINGBO FIRST HOSPITAL

Kit of KL-6 protein on exosomes for auxiliary diagnosis of interstitial lung disease and use thereof

The present application discloses a detection kit of KL-6 protein on exosomes for auxiliary diagnosis of interstitial lung diseases. A detection method includes: after pretreating the exosome sample with a sample treatment solution, exosomes containing KL-6 protein in the sample react with a coated magnetic bead working solution and a luminescent marker-labeled antibody working solution to form an immunocomplex, and a luminous intensity is detected by using a chemiluminescence method and a concentration value is calculated. The application provides, for the first time, a method for diagnosing interstitial pneumonia using a combination of KL-6 and CA125 proteins on exosomes extracted from blood, or using KL-6 alone.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +2

Auxiliary diagnosis method and system for bronchial asthma

The invention discloses an auxiliary diagnosis method and system for bronchial asthma, and relates to the technical field of molecular diagnosis prediction.The auxiliary diagnosis method comprises the steps that an experimental group and a control group are defined, and RNA of the experimental group and RNA of the control group are extracted for low-temperature preservation; carrying out quantitative PCR (Polymerase Chain Reaction) analysis on the RNA stored at low temperature and extracting target cDNA; collecting clinical data of the experimental group and calculating the corresponding biomarker concentration according to the target cDNA; and constructing a bronchial asthma prediction model, outputting a predicted risk probability value of each patient suffering from asthma, and dynamically classifying and adjusting the treatment schemes of the patients. RNA samples of an experimental group and a control group are accurately extracted and stored, remarkably changed gene expression is obtained in combination with quantitative PCR analysis, the gene expression is further combined with biomarker concentration, dynamic monitoring of the asthma-related inflammatory response is successfully achieved, and the bronchial asthma risk of a patient can be accurately evaluated by constructing a bronchial asthma prediction model. And a personalized treatment scheme is provided according to comprehensive analysis of gene expression and biomarkers.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Molecular model for auxiliary diagnosis of diabetic nephropathy established by detecting serum specimens of patients with diabetic nephropathy and non-diabetic nephropathy based on proteomics as well as construction method and application of molecular model

The invention relates to a molecular model for auxiliary diagnosis of diabetic nephropathy based on proteomics detection of serum specimens of patients with diabetic nephropathy and non-diabetic nephropathy as well as a construction method and application of the molecular model, which can effectively screen out biomarkers for auxiliary diagnosis model construction and combine with important clinical variables to construct a clinical auxiliary diagnosis model. According to the technical scheme, the molecular model is formed by combining proteins MTTP, TNNI1 and ANGPTL8, the MTTP ratio of diabetic nephropathy patients to non-diabetic kidney disease patients is 8-12.5, the TNNI1 ratio is 7-15, and the ANGPTL8 ratio is 8-14, the protein composition in a sample is detected through a high-throughput mass spectrum means, and the molecular model has the advantages that the molecular model is simple in structure, convenient to operate and high in sensitivity, and the detection accuracy is high. The difference of a diabetic nephropathy patient group and a non-diabetic nephropathy group in the proteomics level is compared, the biomarker for auxiliary diagnosis model construction is screened out, and a new scheme is provided for auxiliary diagnosis of diabetic nephropathy.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Orthopedic postoperative complication early detection and early warning system based on data analysis

The invention relates to the technical field of medical clinical auxiliary diagnosis, in particular to an orthopedic postoperative complication early detection and early warning system based on data analysis, which comprises a multi-modal sign synchronous acquisition module, a sign dynamic difference quantification module, a complication feature association module, a grading early warning decision module and a dissection calibration visualization module. Wherein the multi-modal sign synchronous acquisition module is used for acquiring postoperative data of a patient; calculating a difference quantization parameter; the complication characteristic association module is used for identifying associated risk characteristics of the osteofascia ventricular syndrome, the deep venous thrombosis and the fat embolism; and the grading early warning decision module is used for generating a three-level early warning instruction based on the associated risk characteristics. According to the system and the method, through a multi-modal sign synchronous acquisition, difference quantification and grading early warning linkage mechanism, accurate recognition, risk grade division and visual intervention guidance of postoperative complications are realized, and the continuity of postoperative monitoring and the timeliness of early warning are improved.
Owner:ZHEJIANG HOSPITAL

Fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.
Owner:CHONGQING KANGJU QUANHONG BIOTECHNOLOGY CO

Kit for breast cancer diagnosis and application thereof

The invention belongs to the technical field of biological medicine, and particularly relates to a kit for breast cancer diagnosis and application thereof. The kit comprises an elisa plate coated with a captured antibody and an HRP labeled antibody working solution, the capture antibody is a monoclonal antibody T2X-1 of an anti-PSTPIP1 protein; the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an anti-PSTPIP1 protein, and the HRP labeled antibody is a monoclonal antibody Z4Y-2 of an The heavy chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.1, and the light chain amino acid sequence of the monoclonal antibody T2X-1 is as shown in SEQ ID NO.2; the heavy chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.3, and the light chain amino acid sequence of the monoclonal antibody Z4Y-2 is as shown in SEQ ID NO.4. The kit for breast cancer diagnosis provided by the invention can be used as an auxiliary diagnosis means for breast cancer with high expression of PSTPIP1 protein, and has high diagnostic value.
Owner:BEIJING OBSTETRICS & GYNECOLOGY HOSPITAL CAPITAL MEDICAL UNIV +1

Recombinant protein and detection reagent for detecting anti-GABABR antibody encephalitis

The invention discloses a recombinant protein and a detection reagent for detecting encephalitis of an anti-GABABR antibody, and belongs to the technical field of neuroimmunology diagnos.A GABABR1 partial sequence, a GABABR2 partial sequence and a transmembrane sequence (and a fluorescent label) are adopted to construct a cell strain for stably and highly expressing the recombinant protein by transfecting CHO cells or HEK293 cells, and the recombinant protein and the detection reagent are used for detecting the encephalitis of the anti-GABABR antibody. The sensitivity and the specificity of the kit in anti-GABABR antibody encephalitis detection can be remarkably improved, the aim of detecting the antibody by using a fixed CBA method or a living cell CBA method can be achieved, and the kit is suitable for auxiliary diagnosis of autoimmune encephalitis of cerebrospinal fluid / serum.
Owner:CHENGDU HAIERYUNYIN MEDICAL LAB CO LTD

Metabolic marker, kit and application of metabolic marker in auxiliary diagnosis of schizophrenia

The invention provides a group of metabolic markers, a kit and application of the metabolic markers in auxiliary diagnosis of schizophrenia. The metabolic markers comprise arachidonic acid, palmitamide and lysophosphatidylcholine (LPC) (17: 0 / 0: 0). By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.
Owner:ZHUMADIAN SECOND PEOPLES HOSPITAL (ZHUMADIAN PSYCHIATRIC HOSPITAL)

Mental disease medical auxiliary diagnosis method based on bimodal knowledge graph and related device

The invention discloses a mental disease medical auxiliary diagnosis method based on a bimodal knowledge graph and a related device, and relates to the technical field of mental disease diagnos.The method comprises the steps that a static medical diagnosis knowledge graph is constructed; generating a scenarized problem library based on the static medical diagnosis knowledge graph; dynamically updating a personal dynamic knowledge graph based on interaction between the scenarized question library and a user; and finally, optimizing the static medical diagnosis knowledge graph based on the personal dynamic knowledge graph. According to the invention, through cooperation of the static and dynamic knowledge maps, objectivity, dynamics and accuracy of mental disease diagnosis are improved, and closed-loop management of medical auxiliary diagnosis is realized.
Owner:BEIHANG UNIV

ERNA molecular marker for auxiliary diagnosis of Crohn disease and application of eRNA molecular marker

The invention discloses an eRNA molecular marker for auxiliary diagnosis of Crohn's disease and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA42767, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention also provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of Crohn's disease, and the kit comprises an eRNA42767 fluorescent quantitative PCR specific amplification primer, the nucleotide sequence of the upstream amplification primer is 5 '-CCTCTCTCTGGACATGCCTA-3', and the nucleotide sequence of the downstream amplification primer is 5 '-CCTATGCGTAGAGATTCTTGCC-3'. The kit has the advantages that early diagnosis of a patient suffering from the Crohn disease on the molecular level is conveniently, quickly and efficiently realized, the pertinence is strong, the specificity is strong, the sensitivity is high, and the kit is beneficial to early discovery and timely treatment of the Crohn disease.
Owner:NINGBO FIRST HOSPITAL

Liver cancer analysis method, system and equipment based on multi-modal deep learning and medium

The invention relates to the technical field of liver cancer analysis, in particular to a liver cancer analysis method, system and equipment based on multi-modal deep learning and a medium. The method comprises the following steps: acquiring pathological data, transcriptome data, methylation data and clinical data of a target patient, and respectively preprocessing to obtain target pathological data, target transcriptome data, target methylation data and target clinical data; respectively carrying out feature extraction to obtain pathological features, transcriptome features, methylation features and clinical features; performing feature fusion on the pathological features, the transcriptome features, the methylation features and the clinical features to obtain liver cancer analysis features; extracting lipid metabolism related marker characteristics of the target patient, and performing liver cancer comprehensive analysis on the target patient according to the lipid metabolism related marker characteristics and the liver cancer analysis characteristics. According to the application, the tumor characteristics of the target patient can be comprehensively reflected, the accuracy of auxiliary diagnosis is improved, and accurate prognosis prediction is provided for the target patient.
Owner:GUANGDONG MEDICAL UNIV

Crohn disease intestinal microbial marker, application thereof and method for constructing Crohn disease detection model

The invention discloses a Crohn disease enteric microorganism marker and application thereof and a method for constructing a Crohn disease detection model.The Crohn disease enteric microorganism marker is characterized in that enteric microorganisms related to Crohn disease are extracted from metagenome data of samples of Crohn disease patients and healthy people; the method comprises the following steps: establishing a random forest model for diagnosing the Crohn disease through the intestinal microbial marker of the Crohn disease, and evaluating to obtain a Crohn disease detection model; according to the method provided by the invention, the treatment effect can be evaluated, the treatment scheme can be adjusted in time, and a new tool is provided for prognosis evaluation of a patient; the specific intestinal microbial marker aiming at the Crohn's disease is found and applied, so that the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of the Crohn's disease are improved, the understanding of the Crohn's disease is deepened, and the development of microbiomics in clinical application is promoted; new biomarkers can be found easily, and new biomarkers or therapeutic targets can be found.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

Detection reagent for detecting depression by sugar chain marker, preparation method and application

The invention provides a detection reagent for detecting depression based on an oligosaccharide chain and a preparation method and application thereof, the detection reagent is prepared by mixing the following reagents: a reagent A, which is prepared by adding SDS with the mass concentration of 1-5% into an ammonium bicarbonate solution with the concentration of 10mM and the pH value of 8.3; the reagent B is prepared by mixing 0.05-10 units / 10 microliters of glycosamine acylase, NP-40 with the mass concentration of 10% and an ammonium bicarbonate solution with the concentration of 10 mM and the pH value of 8.3, and the pH value of the mixed solution is 5-9; the reagent C is an organic matter reducing agent with the concentration of 0.02 mM to 1M, which is prepared by dissolving 8-aminopyrene-1, 3, 6-trisulfonic acid in DMSO (Dimethylsulfoxide); and a reagent D: a stop solution. The invention firstly proposes that the sugar chain map can be used as the auxiliary diagnosis marker of the depression patient, has high sensitivity and high specificity for the diagnosis of depression, has the prospect of being developed into a clinical auxiliary diagnosis kit for depression, can overcome the difficulty and pain point of clinical diagnosis of depression at present, and has a wide application prospect. The method is of great significance to diagnosis and clinical intervention of depression.
Owner:JIANGSU XIANSIDA BIOTECH CO LTD +1

Biomarker for auxiliary diagnosis of lung adenocarcinoma bone metastasis

The invention discloses a biomarker for auxiliary diagnosis of lung adenocarcinoma bone metastasis. The invention specifically provides application of a biomarker or a detection reagent thereof in preparation of a product for auxiliary diagnosis or early screening of lung adenocarcinoma bone metastasis. The biomarker is AA and / or ANGPTL4. According to the invention, AA and / or ANGPTL4 are / is applied to diagnosis of lung adenocarcinoma bone metastasis for the first time, and a simple, non-invasive and long-term available detection method is provided through serum detection; compared with the prior art, earlier bone metastasis diagnosis can be achieved, health risks caused by radiation are avoided, and high clinical application value is achieved; in a word, the invention provides a new biomarker combination for early diagnosis of lung adenocarcinoma bone metastasis, is expected to provide more accurate guidance for clinical treatment of patients, and has important significance for long-term monitoring of tumor metastasis.
Owner:SHANGHAI SIXTH PEOPLES HOSPITAL

Application of synaptic binding protein 11 as marker in preparation of products for diagnosis, auxiliary diagnosis, screening or auxiliary screening of schizophrenia

The invention relates to the technical field of biology, in particular to application of synaptic binding protein 11 serving as a marker to preparation of products for diagnosis, auxiliary diagnosis, screening or auxiliary screening of schizophrenia and application of the synaptic binding protein 11 and / or a dopamine D2 receptor serving as a core target to treatment of schizophrenia. The application of the synaptic binding protein 11 or the transcriptional product mRNA or the mRNA fragment of the synaptic binding protein 11 as the marker in any one of the following items: 1) application in preparation of products for diagnosis or auxiliary diagnosis of schizophrenia of human or non-human mammals; 2) application in preparation of products for screening or auxiliary screening of schizophrenia of human or non-human mammals; 3) application in diagnosis or auxiliary diagnosis of schizophrenia of human or non-human mammals to be detected; and 4) application in screening or auxiliary screening of schizophrenia of human or non-human mammals to be detected. Meanwhile, the invention also provides application of treating three symptoms of schizophrenia through a brain region specific targeting dopamine D2 receptor. Researches find that synaptic binding protein 11 or a transcription product mRNA or mRNA fragment thereof can be used as a brand new functional schizophrenia diagnosis marker, and a chemical molecule or gene therapy drug targeting synaptic binding protein 11 or a dopamine D2 receptor can effectively improve three symptoms of schizophrenia.
Owner:SUZHOU JIELESI BIOTECHNOLOGY CO LTD

Intelligent diagnosis and treatment method and system for juvenile depression based on large model collaboration

The invention provides an intelligent diagnosis and treatment method and system for teenager depression based on large model collaboration, and the method comprises the steps: constructing a remote sensing human living microenvironment and growth soft environment data set, carrying out the preprocessing and feature extraction of the data set, carrying out the space-time matching and characterization of the environment and the brain-behavior clinical data of a subject individual, and carrying out the diagnosis and treatment of the teenager depression. Individual intervention queue data and feature representation matched with the environment are collected; establishing a knowledge graph based on a large model based on the acquired multi-dimensional data; and performing intelligent diagnosis and intervention of environment-brain-behavior enhancement based on the established knowledge graph. Based on a knowledge organization system of environment-brain-behavior auxiliary diagnosis, pathogenesis evaluation and individualized intervention, an environment-brain-behavior multi-dimensional knowledge graph oriented to adolescent depression diagnosis is constructed, and based on a large-model collaborative reasoning mechanism enhanced by environment-brain-behavior multi-dimensional knowledge, the adolescent depression diagnosis is more accurate. An intelligent and precise method system is provided for diagnosis and treatment of juvenile depression, and the diagnosis and treatment level is greatly improved.
Owner:RENMIN HOSPITAL OF WUHAN UNIVERSITY (HUBEI GENERAL HOSPITAL)

Application of hsacirc0008581 as biomarker for esophageal cancer auxiliary diagnosis and / or esophageal cancer patient prognosis prediction

The invention discloses an application of circular RNA (Ribonucleic Acid) hsacirc0008581 as a biomarker for auxiliary diagnosis of esophageal cancer and / or prognosis prediction of esophageal cancer patients. The circular RNA hsacirc0008581 is highly expressed in esophageal cancer tumor tissues, the highly expressed hsacirc0008581 can significantly promote the increase of malignant phenotypes such as invasion, migration, metastasis and the like of esophageal cancer cells, and meanwhile, the high expression level of the hsacirc0008581 is significantly related to the shorter total lifetime of esophageal cancer patients, that is, the hsacirc0008581 can be used as an independent risk prognosis prediction factor of the esophageal cancer patients. Therefore, the hsacirc0008581 can be used as a novel biomarker for effectively assisting in diagnosing the esophageal cancer and / or predicting the metastasis risk and / or the total lifetime of the esophageal cancer patient and a novel target for treating the esophageal cancer.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

Blood marker for identifying epilepsy convulsion and application thereof

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.
Owner:SHENZHEN PEOPLES HOSPITAL

Trypsinogen-2 detection method and kit based on homogeneous light-activated chemiluminescence immunoassay technology

The invention discloses a trypsinogen-2 detection method and kit based on a homogeneous light-excited chemiluminescence immunoassay technology, and belongs to the technical field of immunodetection analysis. The method provided by the invention comprises the following steps: preparing donor microspheres and receptor microspheres coupled with a trypsinogen-2 capture antibody, adding the coupled donor microspheres and receptor microspheres into a sample to be detected, uniformly mixing and incubating without cleaning, and finally detecting by using a fluorescence detector. The kit comprises donor microspheres coupled with a trypsinogen-2 capture antibody, receptor microspheres coupled with a trypsinogen-2 detection antibody, a trypsinogen-2 standard substance solution and an analysis buffer solution. The trypsinogen-2 content in a sample to be detected can be rapidly detected by using the characteristics of a double-antibody sandwich immunoassay and light-activated chemiluminescence, and the trypsinogen-2 detection kit has the characteristics of wide detection range, high sensitivity, high accuracy, rapid and simple detection and the like, can be used for early auxiliary diagnosis of acute pancreatitis clinically, and has a relatively good application prospect.
Owner:ZHEJIANG XIAOSHAN HOSPITAL

Active tuberculosis diagnostic marker, kit and application thereof

The invention discloses an active tuberculosis diagnostic marker, a kit and application thereof. In particular to application of a reagent for detecting a diagnostic marker in preparation of a kit for diagnosing active tuberculosis, the diagnostic marker is a biomarker TRIM22 in a blood sample, and the sequence of the TRIM22 is as shown in SEQ ID NO: 1. According to the invention, TRIM22 in a blood sample is used as a biomarker for detecting active tuberculosis for the first time. Results of ROC curve analysis show that the expression level of TRIM22 in whole blood has good sensitivity and specificity for active tuberculosis diagnosis. Therefore, the invention overcomes the defects of low detection rate, long time consumption and the like of the existing active tuberculosis diagnosis, has the characteristics of good specificity and high sensitivity, and has good clinical application value for the auxiliary diagnosis of the active tuberculosis.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

Pancreatic cancer early screening marker combination and application thereof

The invention relates to the technical field of tumor markers, in particular to a pancreatic cancer early screening marker combination based on blood protein and application of the pancreatic cancer early screening marker combination. Through proteomics analysis and bioinformatics screening, 12 kinds of proteins such as NME3, HPGDS, CEACAM5, TNFSF12, SCG3, VTCN1, GFRA1, KRT19, TMPRSS12, NELL2, KAZALD and MMP12 are determined to serve as the potential early screening markers of the pancreatic cancer. Researches show that the combination of the proteins can effectively distinguish pancreatic cancer patients from non-pancreatic cancer patients, and has good sensitivity and specificity. A screening model constructed based on the protein combination can be applied to auxiliary diagnosis, risk assessment and population screening of pancreatic cancer, and has important clinical transformation value.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Microbial marker for cervical cancer and application thereof

The invention provides a plurality of microbial markers for cervical cancer and an application of the microbial markers. The microbial markers comprise 11 bacteria, namely, Porphyromonas aeruginosa, Lactobacillus crispatus, Klebsiella pneumoniae, Gemerella haemolysms and the like, and the microbial markers comprise 11 bacteria, namely, the Porphyromonas aeruginosa, the Lactobacillus crispatus, the Klebsiella pneumoniae, the Gemerella haemolysms and the like. According to the method, the threshold value of the output risk value is obtained according to the trained random forest model, and then the probability value that the cervical lesion sample is the high-risk lesion can be obtained only by obtaining the relative abundance of the screened 11 genital tract microbial markers and inputting the relative abundance into the established random forest model. The machine learning model is constructed based on 16S sequencing, the high risk of cervical cancer can be recognized in time, the method is used for auxiliary diagnosis of cervical cancer patients, early discovery, early prevention and early treatment of cervical cancer are facilitated, and the accessibility of cervical cancer screening is improved.
Owner:SHENYOU GENOME RES INST (NANJING) CO LTD